IMPLEMENTACIÓN Y OPERACIÓN

64

65

 Patients to be administered combination therapy should be counselled on the increased risk of side effects.

 Patients should be educated on the mode of action of these drugs and duration required for the effect to be noticed in order to improve compliance.

66

REFERENCES

1. Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology,Epidemiology, and Natural History. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell Walsh Urology. 10 ed. United States of America: Saunders Elsevier; 2012. p.

2570-2694.

2. Yeboah E.D. Principles And Practice Of Surgery Including Pathology In The Tropics. In: E.A. Badoe, E.Q. Archampong, Rocha-Afodu JTd, editors. 3 ed. Ghana: Ghana Publishing Corporation; 2000. p. 850-866.

3. Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, et al.

Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation. Niger Postgrad Med J;. 2011;18(2):98-104.

4. Ezeanyika L, Ejike E, Obidoa O, Elom S. Prostate disorders in an apparently normal Nigerian population 1:Prevalence. BIOKEMISTRI 2006;18(2):127-132.

5. el Din KE, Koch WF, de Wildt MJ, Kiemeney LA, Debruyne FM, et al.

Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol. 1996;155(6):1959-1964.

67

6. Quek KF, Low WY, Razack AH, Loh CS. Reliability and validity of the International Prostate Symptom Score in a Malaysian population. BJU Int.

2001;88(1):21-25.

7. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, et al.

Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175(4):1422-1426.

8. Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, et al. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia Arch Ital Urol Androl. 2009 81(1):1-8.

9. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate cancer and prostatic diseases. 1999; 2:110-119.

10. Andersen JT, Ekman P, Wolf H, Beisland H.O., Johansson J.E, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo controlled study.The Scandinavian BPH study Group. . Urology.

1995;46:631-637.

11. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double blind, placebo- controlled, multicenter study, PROWESS Study Group. . Urology 1998;51:677-686.

68

12. McConnell JD, Bruskewitz R, Walsh PC, Gerald Andriole, Michael Lieber, et al. The effect of finasteride on the risk of urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia (PLESS). . N Engl J Med 1998; 338:557-563.

13. Nickel J, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2 year randomised controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two Year Study. Can Med Assoc J.

1996;155:1252-1259.

14. Foley SJ, Soloman LZ, Wedderburn AW, et al. Finasteride for haematuria due to BPH. A prospective study of the natural history of haematuria associated with BPH and the effect of finasteride. J Urol 2000;163:496-498.

15. McNeill SA, Daruwala PD, Mitchell IDC, Shearer, Hargreave. Sustained-release alfuzosin and trial without catheter after acute urinary retention: A prospective, placebo-controlled trial. BJU Int 1999; 84:622-627.

16. John D. McConnell, Claus G. Roehrborn, Oliver M. Bautista, Gerald L.

Andriole, Christopher M. Dixon, et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia:Medical Therapy of Prostatic Symptoms (MTOPS) N Engl J Med 2003;349:2387-2398.

69

17. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57(1):123-131.

18. Debruyne FM, Jardin A CD, Resel L, Witjes WP, et al. Sustained release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia.European ALFIN Study Group. Eur Urol.

1998;34:169-175.

19. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazocin and Combination Therapy(PREDICT) trial. Urology.

2003;61(1):119-126.

20. Wikipedia. Efficacy. United States of America: Wikipedia Foundation Inc.; [updated 23/4/13; cited 2013 25/5/2013]; Available from:

http://en.wikipedia.org/wiki/Efficacy.

21. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.

70

22. Horchani A BM, Ben Hamida A, Sallami S, El Adbi H, Naji A. Prevalence of benign prostatic hyperplasia in general practice and practical approach of the Tunisian general practitioner (Prevapt study). Tunis Med.

2007;85(8):619-624.

23. Obiorah CC, Nwosu SO. Histopathologic characterisation of prostate diseases in Port Harcourt. Niger Postgrad Med J 2009 Jun;16(2):158-161.

24. Abrams P. New words for old-lower urinary tracts symptoms for prostatism. Br Med J. 1994;308:929-930.

25. Hansen BJ, Mortensen S, Mensink HJ, Flyger H, Riehmann M, et al.

Comparison of the Danish prostatic symptom score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. BJ Urol. 1998;81(1):36–41.

26. Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia Urology. 2001;58(6):25–32.

27. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, et al. Correlation of the American Urological Association Symptom Index with self-administered versions of the Madsen-Iverson, Boyarsky and Maine Medical Assessment Program Symptom Indexes. J Urol.

1992;148:1558-1563.

71

28. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992;148:1549-1557.

29. Reynard J, Yang Q, Donovan JL, Peters TJ, Schafer W, et al. The ICS-BPH study:uroflometry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. 1998;82:619-623.

30. McConnell J, Barry M, Bruskewitz R, et al. Benign Prostatic Hyperplasia:

Diagnosis and Treatment. Clinical Practice Guideline. No. 8. (AHCPR publication No. 94-0582.) Rockville, Md, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services 1994.

31. Probert JL. Evaluation of lower urinary tract symptom. In: Probert JL, editor. Atlas of Investigation and Diagnosis Urology. United Kingdom:

Clinical Publishing Oxford; 2009. p. 32-37.

32. American Urological Association Education and Research Inc. Guideline on the management of benign prostatic hyperplasia (BPH). Linthicum (MD). 2010:34.

33. Mebust WK, Holtgrewe HL, Cockett ATK, Peters P. C. Transurethral prostatectomy: Immediate and postoperative complications: A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol.

1989;141:243-247.

72

34. Koch W, Ezz el Din K, de Wildt M, Debruyne F, de la Rosette J. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol 1996 155(1):186-189.

35. Mukamel E, Nissenkorn I, Boner G, Servadio C. Occult progressive renal damage in the elderly male due to benign prostatic hypertrophy. J Am Geriatr Soc. 1979 27(9):403-406.

36. Malemo K, Galukande M, Hawkes M, Bugeza S, Nyavandu K, Kaggwa S.

Validation of supra-pubic ultrasonography for preoperative prostate volume measurement in sub-Saharan Africa. Int Urol Nephrol 2011 43(2):283–288.

37. Ball A, Feneley R, Abrams P. The natural history of untreated "prostatism".

Br J Urol. 1981 53(6):613-616.

38. Wasson J, Reda D, Bruskewitz R, Elinson J, Keller A, Henderson W. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995 12;332(2):75-79.

39. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. . Br J Urol.

1975;27:193-202.

73

40. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomised trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001;58(5):717-722.

41. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. . Urology.

1998;51(6):892-900.

42. Nwofor AME, Dogunro AS. Doxazosin in the treatment of elderly patients with benign prostatic hyperplasia. African Journal of Urology. 2002;8:56-61.

43. Jeje EA , Dogunro AS, Ogunjimi MA, Tijani KH. Efficacy and Safety of Doxazosin (CARDURATM) in the Management of Benign Prostatic Hyperplasia. Nigerian Journal of Surgery. 2011;17(2):55-59.

44. Wilt T, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects. . J Urol 2002;167:177-183.

45. Claus G. Roehrborn. ALTESS study:Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study BJUI 2006;97(4): 734–741.

74

46. Lukacs B, Grange JC, Comet D, McCarthy C. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol 2000;37:183-190. .

47. McConnell J, Roehborn C, Baustista O, Andriole GL Jr, Dixon C, et al.

The long-term effect of doxazocin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.

48. Vermeulen A, Giagulli VA, Schepper PD, Buntinx A, Stoner El. Hormonal effects of an orally active 4-azasteroid inhibitor or 5-alpha reductase in humans Prostate. 1989;14(1):45-53.

49. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW.

Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest 1992;89:293-300.

50. Thigpen A, Silver R, Guileyardo J, Casey ML, McConnell JD, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

J Clin Invest 1993;92:903-910.

51. Clark R, Hermann D, Gabriel H. Effective suppression of dihydrotestosterone (DHT) G1198745, a novel, dual 5-alpha reductase inhibitor (abstract 1037). J Urol 1999;161:268.

75

52. Andriole G, Bruchovsky N, Chung L, Matsumoto A, Rittmaster R, et al.

Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399.

53. McConnell J, Wilson J, George F, Geller J, Pappas F, et al. Finasteride, and inhibitor of 5 alpha Reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505.

54. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 2007;10(2):149-154.

55. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987 317(10):599-604.

56. Gormley G, Stoner E, Bruskewitz R, Imperato-McGinley J, Walsh P, et al.

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 327(17):1185-1191.

57. Lowe F, McConnell J, Hudson P, Romas N, Boake R, et al. Finasteride Study Group Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61(4):791-796.

76

58. Nickel J, Gilling P, Tammela T, Morrill B, Wilson T, Rittmaster R.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388-394.

59. Petros P, Kostis G, Spyros M, George B. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology.

2002;59(3):373–377.

60. Puchner P, Miller M. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: A preliminary report. J Urol.

1995;154:1779-1782.

61. Lepor H, Williford W, Barry M, Brawer M, Dixon C, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533-539.

62. Kirkwood RB, Sterne ACJ. Essential Medical Statistics. In: Kirkwood RB, Sterne ACJ, editors. Essential Medical Statistics. united state of America:

Blackwell Publishing Company; 2003. p. 418.

77

63. Nacey J, Meffan P, Delahunt B. The Effect Of Finasteride On Prostate Volume, Urinary Flow Rate And Symptom Score In Men With Benign Prostatic Hyperplasia. Australian and New Zealand Journal of Surgery.

1995;65(1):35-39.

64. Marks L, Partin A, Gormley G, Dorey F, Shery E, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol. 1997;157(6):2171-2178.

78

APPENDIX I

COMPARATIVE STUDY OF THE EFFICACY OF